Top 3 drug approvals in oncology in May: durvalumab, pembrolizumab and cemiplimab

Imfinzi® (durvalumab) Approved: 16 May 2022 Approving body: National Institute for Health and Care Excellence (NICE) Indication: Locally advanced Stage III NSCLC Imfinzi (durvalumab) produced by AstraZeneca (London, UK) was recommended as a monotherapy option for locally advanced Stage III NSCLC via the NHS in England by NICE this month. The drug was previously made available via the Cancer Drug Fund in May 2019. The latest recommendation from NICE comes as a result of encouraging data from the PACIFIC Phase III trial. A collective review of 5 years of data highlighted that the median progression-free survival was <2 years for...